AstraZeneca PLC (AZN)vsAlpha Teknova Inc (TKNO)
AZN
AstraZeneca PLC
$185.95
+0.86%
HEALTHCARE · Cap: $282.69B
TKNO
Alpha Teknova Inc
$5.13
-0.97%
HEALTHCARE · Cap: $235.90M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 144484% more annual revenue ($60.44B vs $41.80M). AZN leads profitability with a 17.2% profit margin vs -41.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TKNO
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.1%
Fair Value
$194.57
Current Price
$185.95
$8.62 discount
Intrinsic value data unavailable for TKNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TKNO
The strongest argument for TKNO centers on Debt/Equity. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while TKNO is a turnaround play — different risk/reward profiles.
TKNO carries more volatility with a beta of 0.63 — expect wider price swings.
TKNO is growing revenue faster at 13.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology sector, specializing in the production of vital biological reagents and supplements that cater to life sciences research and biomanufacturing. The company's offerings play a pivotal role in high-demand areas such as vaccine development, cell and gene therapy, and diagnostic testing, underscored by a commitment to quality and exceptional customer service. With a robust biotechnology foundation and a strong focus on innovation, Alpha Teknova is well-equipped to capitalize on growth opportunities in the rapidly evolving life sciences market, positioning itself as a valuable investment for institutional stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?